Department of Urology, Northampton General Hospital, Cliftonville Road, Northampton, NN1 5BD, UK.
Future Oncol. 2012 Sep;8(9):1073-81. doi: 10.2217/fon.12.99.
Prostate cancer is the most common solid organ cancer affecting the male population. Men with metastatic prostate cancer treated with androgen ablation therapy often respond rapidly, with improvement in bone pain and decreases in serum prostate-specific antigen. However, almost all patients progress to the castration-resistant state and abiraterone acetate was the last treatment available with proven survival benefit. Enzalutamide (formerly MDV3100) is an androgen receptor signaling inhibitor that has been shown to improve survival in men with metastatic castration-resistant prostate cancer previously treated with chemotherapy. In this article we discuss the characteristics of enzalutamide and provide a review of its clinical development.
前列腺癌是影响男性人群的最常见实体器官癌症。接受雄激素剥夺疗法治疗的转移性前列腺癌男性患者通常会迅速响应，骨痛改善，血清前列腺特异性抗原降低。然而，几乎所有患者都会进展为去势抵抗状态，阿比特龙是唯一具有生存获益的治疗方法。恩扎卢胺（前称 MDV3100）是一种雄激素受体信号抑制剂，已被证明可改善先前接受化疗的转移性去势抵抗前列腺癌男性患者的生存。本文讨论了恩扎卢胺的特点，并对其临床开发进行了综述。
